Global biopharmaceuticals market will reach $1,001.1 billion by 2033, growing by 8.8% annually over 2023-2033. The growth is driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing clinical trials and approvals for novel biomedicines, escalating healthcare spending, and favorable reimbursement policies.
Highlighted with 78 tables and 119 figures, this 215-page report "Global Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service, Raw Material (Excipients, API, Others), Classification (Innovative, Biogenerics and Biosimilars), Therapeutic Area, and Region: Trend Forecast and Growth Opportunity" is based on comprehensive research of the entire global biopharmaceuticals market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2023 and provides a forecast from 2024 till 2033 with 2023 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter's Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify the global biopharmaceuticals market in every aspect of the classification from perspectives of Product Type, Testing Service, Raw Material, Classification, Therapeutic Area, and Region.
Based on Product Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Monoclonal Antibodies
o Anti-cancer Monoclonal Antibodies
o Anti-inflammatory Monoclonal Antibodies
o Other Monoclonal Antibodies
• Recombinant Growth Factors
o Erythropoietin
o Granulocyte Colony Stimulating Factor
• Purified Proteins
o Leukemia Inhibitory Factor (LIF)
o P53 Protein
o P38 Protein
o Other Purified Proteins
• Recombinant Proteins
o Serum Albumin
o Amyloid Protein
o Defensin
o Transferrin
• Recombinant Hormones
o Recombinant Human Growth Hormones
o Recombinant Insulin
o Other Recombinant Hormones
• Vaccines
o Recombinant Vaccines
Cancer Vaccines
Malaria Vaccines
Ebola Vaccines
Hepatitis Vaccines
Tetanus Vaccines
Diphtheria Vaccines
Cholera Vaccines
Other Recombinant Vaccines
o Conventional Vaccines
Polio Vaccines
Pox Vaccines
Other Conventional Vaccines
• Recombinant Enzymes
o Enterokinase
o Cyclase
o Caspase
o Cathepsin
• Cell and Gene Therapies
o Allogenic Products
o Autologous Products
o Acellular Products
• Synthetic Immunomodulators
• Other Product Types
o Blood Factors
o Other Products
Based on Testing Service, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Laboratory Testing
• Custom Testing/Customer Proprietary Testing
• Compendial and Multi Compendial Laboratory Testing
By Raw Material, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Formulation Excipients
• Active Pharmaceutical Ingredients (API)
• Other Materials
By Classification, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Innovative Biopharmaceuticals
• Biogenerics and Biosimilars
By Therapeutic Area, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Oncology
• Inflammatory and Infectious Diseases
• Autoimmune Disorders
• Metabolic Disorders
• Hormonal Disorders
• Cardiovascular Diseases
• Neurological Diseases
• Other Therapeutic Areas
Geographically, the following regions together with the listed national/local markets are fully investigated:
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Netherlands, Rest of Europe; Rest of Europe is further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa, and Rest of MEA)
For each region and country, detailed analysis and annual revenue ($ mn) are available for 2023-2033. The breakdown of all regional markets by country and the breakdown of each national market by Product Type and Therapeutic Area over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott Laboratories
Amgen Inc.
Astrazeneca PLC
Bayer AG
Biogen Inc.
Bristol-myers Squibb Company (BMS)
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Glaxosmithkline PLC
Johnson & Johnson
Merck & Co. Inc.
Novartis Ag
Novo Nordisk As
Pfizer Inc.
Sanofi Sa
Sharp Packaging Services
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals
WuXi AppTec
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 Introduction 11
1.1 Industry Definition and Research Scope 11
1.1.1 Industry Definition 11
1.1.2 Research Scope 12
1.2 Research Methodology 15
1.2.1 Overview of Market Research Methodology 15
1.2.2 Market Assumption 16
1.2.3 Secondary Data 16
1.2.4 Primary Data 16
1.2.5 Data Filtration and Model Design 17
1.2.6 Market Size/Share Estimation 18
1.2.7 Research Limitations 19
1.3 Executive Summary 20
2 Market Overview and Dynamics 23
2.1 Market Size and Forecast 23
2.1.1 Impact of COVID-19 on World Economy 24
2.1.2 Impact of COVID-19 on the Market 28
2.1.3 Impact of Russia-Ukraine Conflict 30
2.1.4 Impact of Israel-Palestine War 32
2.2 Major Growth Drivers 33
2.3 Market Restraints and Challenges 42
2.4 Emerging Opportunities and Market Trends 45
2.5 Porter's Fiver Forces Analysis 49
3 Segmentation of Global Market by Product Type 53
3.1 Market Overview by Product Type 53
3.2 Monoclonal Antibodies 55
3.2.1 Anti-cancer Monoclonal Antibodies 56
3.2.2 Anti-inflammatory Monoclonal Antibodies 57
3.2.3 Other Monoclonal Antibodies 58
3.3 Recombinant Growth Factors 59
3.3.1 Erythropoietin 60
3.3.2 Granulocyte Colony Stimulating Factor 61
3.4 Purified Proteins 62
3.4.1 Leukemia Inhibitory Factor (LIF) 63
3.4.2 P53 Protein 64
3.4.3 P38 Protein 65
3.4.4 Other Purified Proteins 66
3.5 Recombinant Proteins 67
3.5.1 Serum Albumin 68
3.5.2 Amyloid Protein 69
3.5.3 Defensin 70
3.5.4 Transferrin 71
3.6 Recombinant Hormones 72
3.6.1 Recombinant Human Growth Hormones 73
3.6.2 Recombinant Insulin 75
3.6.3 Other Recombinant Hormones 76
3.7 Vaccines 77
3.7.1 Recombinant Vaccines 78
3.7.2 Conventional Vaccines 80
3.8 Recombinant Enzymes 81
3.8.1 Enterokinase 82
3.8.2 Cyclase 83
3.8.3 Caspase 84
3.8.4 Cathepsin 85
3.9 Cell and Gene Therapies 86
3.9.1 Allogenic Products 87
3.9.2 Autologous Products 88
3.9.3 Acellular Products 89
3.10 Synthetic Immunomodulators 90
3.11 Other Product Types 91
3.11.1 Blood Factors 92
3.11.2 Other Products 93
4 Segmentation of Global Market by Testing Service 94
4.1 Market Overview by Testing Service 94
4.2 Laboratory Testing 96
4.3 Custom Testing/Customer Proprietary Testing 97
4.4 Compendial and Multi Compendial Laboratory Testing 98
5 Segmentation of Global Market by Raw Material 99
5.1 Market Overview by Raw Material 99
5.2 Formulation Excipients 101
5.3 Active Pharmaceutical Ingredients (API) 102
5.4 Other Materials 103
6 Segmentation of Global Market by Classification 104
6.1 Market Overview by Classification 104
6.2 Innovative Biopharmaceuticals 106
6.3 Biogenerics and Biosimilars 107
7 Segmentation of Global Market by Therapeutic Area 108
7.1 Market Overview by Therapeutic Area 108
7.2 Oncology 110
7.3 Inflammatory and Infectious Diseases 111
7.4 Autoimmune Disorders 112
7.5 Metabolic Disorders 113
7.6 Hormonal Disorders 114
7.7 Cardiovascular Diseases 115
7.8 Neurological Diseases 116
7.9 Other Therapeutic Areas 117
8 Segmentation of Global Market by Region 118
8.1 Geographic Market Overview 2023-2033 118
8.2 North America Market 2023-2033 by Country 122
8.2.1 Overview of North America Market 122
8.2.2 U.S. 126
8.2.3 Canada 129
8.2.4 Mexico 131
8.3 European Market 2023-2033 by Country 133
8.3.1 Overview of European Market 133
8.3.2 Germany 137
8.3.3 U.K. 139
8.3.4 France 141
8.3.5 Spain 143
8.3.6 Italy 145
8.3.7 Netherlands 147
8.3.8 Rest of European Market 149
8.4 Asia-Pacific Market 2023-2033 by Country 151
8.4.1 Overview of Asia-Pacific Market 151
8.4.2 Japan 155
8.4.3 China 158
8.4.4 Australia 160
8.4.5 India 162
8.4.6 South Korea 164
8.4.7 Rest of APAC Region 166
8.5 South America Market 2023-2033 by Country 168
8.5.1 Argentina 171
8.5.2 Brazil 173
8.5.3 Chile 175
8.5.4 Rest of South America Market 177
8.6 MEA Market 2023-2033 by Country 178
8.6.1 UAE 181
8.6.2 Saudi Arabia 183
8.6.3 South Africa 185
8.6.4 Other National Markets 187
9 Competitive Landscape 188
9.1 Overview of Key Vendors 188
9.2 New Product Launch, Partnership, Investment, and M&A 192
9.3 Company Profiles 193
Abbott Laboratories 193
Amgen Inc. 195
Astrazeneca PLC 196
Bayer AG 197
Biogen Inc. 198
Bristol-myers Squibb Company (BMS) 199
Eli Lilly and Company 200
F. Hoffmann-La Roche Ltd. 201
Glaxosmithkline PLC 202
Johnson & Johnson 203
Merck & Co. Inc. 204
Novartis Ag 205
Novo Nordisk As 206
Pfizer Inc. 207
Sanofi Sa 208
Sharp Packaging Services 209
Sun Pharmaceutical Industries Ltd. 210
Takeda Pharmaceutical Company Limited 211
Thermo Fisher Scientific Inc. 212
Vertex Pharmaceuticals 213
WuXi AppTec 214
RELATED REPORTS 215
The High Purity Process Systems for Biopharmaceuticals Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competi...
The Membrane Materials for Biopharmaceuticals Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive land...
Asia Pacific biopharmaceuticals market will grow by 10.3% annually with a total addressable market cap of $1,776.7 billion over 2024-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discove...
Europe biopharmaceuticals market was valued at $116.5 billion in 2023 and will grow by 8.6% annually over 2023-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing clinical t...
North America biopharmaceuticals market is projected to grow by 8.4% annually in the forecast period and reach $407.2 billion by 2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, ...
Global biopharmaceuticals market will reach $1,001.1 billion by 2033, growing by 8.8% annually over 2023-2033. The growth is driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing cl...
Overview of the Global Digital Manufacturing in Biopharmaceuticals Market:
The report discusses everything a marketer requires before investing in the global Digital Manufacturing in Biopharmaceuticals Market during...
Overview of the Global Biopharmaceuticals Last-Mile Delivery Market:
The report discusses everything a marketer requires before investing in the global Biopharmaceuticals Last-Mile Delivery Market during the forecas...
The global Cancer Biopharmaceuticals market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in...
The global Non-oncology Biopharmaceuticals market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market play...